Tivicay 5mg dispersible tablets

*
Pharmacy Only: Prescription
  • Company:

    ViiV Healthcare UK Ltd
  • Status:

    No Recent Update
  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)
  • Active Ingredient(s):

    *Additional information is available within the SPC or upon request to the company

Updated on 12 July 2024

File name

ie-pl-tivicay5mg-issue8draft1-clean-no headers.pdf

Reasons for updating

  • Change to section 4 - how to report a side effect

Updated on 12 July 2024

File name

ie-spc-tivicay5mg-issue10draft1-clean-no headers.pdf

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 26 July 2023

File name

ieukni-spc-tivicay5mg-issue9draft1-clean.pdf

Reasons for updating

  • Change to section 5.2 - Pharmacokinetic properties

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 05 October 2022

File name

ieukni-spc-tivicay5mg-issue8draft1-clean.pdf

Reasons for updating

  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 22 September 2022

File name

ieukni-spc-tivicay5mg-issue7draft1-clean.pdf

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 22 September 2022

File name

ieukni-pl-tivicay5mg-issue7draft1-clean.pdf

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 06 September 2022

File name

ieukni-spc-tivicay5mg-issue6draft1-workingcopy-clean_emc.pdf

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 06 September 2022

File name

ieukni-pl-tivicay5mg-issue6draft1-workingcopy-clean_emc.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 6 - date of revision

Updated on 02 December 2021

File name

ieukni-spc-combined-tivicay5mg-issue4draft1.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 02 December 2021

File name

ieukni-pl-combined-tivicay5mg-issue4draft1.pdf

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 07 October 2021

File name

ieukni-spc-tivicay5mg-issue3draft1.pdf

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.1 - List of excipients
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 5.1 - update to ATC code and information relating to the week 144 data from Gemini studies

Section 6.1 - update to the excipient naming

Updated on 07 October 2021

File name

ieukni-pl-tivicay5mg-issue3draft1.pdf

Reasons for updating

  • Change to section 6 - what the product contains
  • Change to further information section
  • Change to date of revision

Updated on 17 February 2021

File name

ie-spc-tivicay5mg-issue2draft1.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4 - addition of bilirubin ADR as a result of the final clinical study report

Updated on 17 February 2021

File name

ie-pl-tivicay5mg-issue2draft1.pdf

Reasons for updating

  • Change to section 4 - possible side effects

Free text change information supplied by the pharmaceutical company

Section 4 - addition of bilirubin ADR as a result of the final clinical study report

 

Updated on 17 February 2021

File name

ie-spc-tivicay5mg-issue1draft1.pdf

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 17 February 2021

File name

ie-pl-tivicay5mg-issue1draft1.pdf

Reasons for updating

  • New PIL for new product